Boehringer, BioMed X Enter COPD Pact

Boehringer Ingelheim and BioMed X have entered a collaboration to establish a research group focused on identifying novel therapeutic concepts for treating chronic obstructive pulmonary disease (COPD). Further details and financial terms were not disclosed.
 
The companies will jointly select the best ideas and life science talents to form a new research group within BioMed X’s open innovation lab in Heidelberg. BioMed X has developed an innovation model offering a project plan, funding package, entrepreneurial education and guidance by experienced mentors from academia and Boehringer Ingelheim. The winners of the project plan competition will have access to BioMed X’s lab to develop treatment opportunities for COPD patients.
 
BioMed X will be responsible for recruitment of the new research group, the operation of the innovation center facility, providing entrepreneurial education and enabling access to the Heidelberg scientific community and research facilities.
 
“We welcome Boehringer Ingelheim as additional pharmaceutical partner to our Innovation Center,” said Christian Tidona, founder and Managing Director of BioMed X. “This is a major milestone in our endeavor to bridge the translational gap between academia and the pharmaceutical industry.”